AVIR at a glance
Atea Pharmaceuticals, Inc. (AVIR, SEC CIK 1593899) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and Form 4 insider filings as recently as June 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Atea Pharmaceuticals, Inc. (AVIR) shares worth $161.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $161.2M · −1 vs prior quarter
- Latest 8-K
- Aug 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no approved products or product sales
- Net loss $32.9M vs $37.2M YoY; operating loss $35.1M vs $41.3M
- HCV external R&D $17.9M vs $24.3M; HEV external R&D $2.9M vs $0
- Cash, equivalents and marketable securities $219.5M; operating cash use $83.5M for six months
- C-FORWARD results expected early Q1 2027; FDA NDA submission targeted Q2 2027
Risk Factors
- HCV lead program depends on C-FORWARD Phase 3 success, with topline results expected early Q1 2027
- Regulatory approval risk includes potential FDA requirements for additional clinical trials or studies before HCV commercialization
- Liquidity risk: $78.4 million net loss in six months ended June 30, 2026, with no product revenue
- Operational risk: COVID-19 development discontinued after SUNRISE-3 failed its primary endpoint in 2,221 patients
- Financial concentration: majority of cash held at U.S. banks, potentially exceeding the FDIC’s $250,000 insurance limit
AI summary of the AVIR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results announced for the three months ended June 30, 2026
- Detailed financial figures and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- C-BEYOND met non-inferiority: BEM/RZR SVR 93.9% vs 94.8% for SOF/VEL in 905 patients
- Eight-week BEM/RZR achieved 93.5% SVR in non-cirrhotic patients vs 94.6% for 12-week SOF/VEL
Item 5.07: Submission of Matters to a Vote of Security Holders
- 74.65% of outstanding shares represented at June 18 annual meeting, providing strong shareholder participation
- Jerome Adams, Howard Berman and Barbara Duncan elected Class III directors through 2029
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results for three months ended March 31, 2026
- Press release issued May 12, 2026 with results and additional company matters
AI summaries of AVIR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AVIR
Don't miss the next AVIR filing
- Alerts as it files. A push when AVIR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AVIR, by share count.
- Ask anything. An AI agent that reads every AVIR filing and answers with sources.
AVIR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Berman Howard | A | Jun 18, 2026 | 26,700 | - |
| Berman Howard | A | Jun 18, 2026 | 37,700 | - |
| Adams Jerome M. | M | Jun 18, 2026 | 29,600 | - |
| Adams Jerome M. | M | Jun 18, 2026 | 29,600 | - |
| Adams Jerome M. | A | Jun 18, 2026 | 26,700 | - |
| Adams Jerome M. | A | Jun 18, 2026 | 37,700 | - |
| BERGER FRANKLIN M | M | Jun 18, 2026 | 29,600 | - |
| BERGER FRANKLIN M | M | Jun 18, 2026 | 29,600 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$164.2M | -$192.9M | -$180.9M | |
| Net Income | -$136.0M | -$168.4M | -$158.3M | |
| Balance Sheet | ||||
| Total Assets | $595.0M | $464.7M | $315.2M | |
| Equity | $555.2M | $438.9M | $275.4M | |
| ROE | -24.5% | -38.4% | -57.5% | |
| Per Share | ||||
| EPS | $-1.63 | $-2.00 | $-1.94 | |
| Cash Flow | ||||
| Operating CF | -$85.4M | -$135.5M | -$132.0M | |
Source: XBRL data in Atea Pharmaceuticals, Inc. (AVIR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AVIR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $161.2M |
| Q1 2026 | 25 | $184.9M |
| Q4 2025 | 22 | $115.5M |
| Q3 2025 | 24 | $82.6M |
| Q2 2025 | 24 | $98.2M |
| Q1 2025 | 20 | $54.9M |
| Q4 2024 | 15 | $57.3M |
| Q3 2024 | 13 | $20.6M |
- BlackRock+284.6K (+3%)
- AQR Capital Management+201.6K (+437%)
- Northern Trust+170.2K (+29%)
- Invesco Ltd+133.8K (+100%)
- Citadel Advisors LLC+108.8K (+225%)
- Two Sigma Investments−357.5K (-19%)
- Vanguard Capital Management LLC−281.3K (-9%)
- Goldman Sachs Group−57.6K (-10%)
- Millennium Management−45.3K (-13%)
- State Street Corp−42.2K (-2%)
- U.S. Bancorp−64
Source: 13F-HR filings on SEC EDGAR (aggregated from 167 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AVIR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | May 21, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Mar 13, 2026 | - | - | - |
| 10-K | Mar 5, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 5, 2026 | - | Analysis | - |
| SC 13G | Feb 9, 2026 | - | - | |
| 4 | Feb 3, 2026 | - | - | |
| 4 | Feb 3, 2026 | - | - | |
| 4 | Feb 3, 2026 | - | - | |
| 4 | Feb 3, 2026 | - | - | |
| 4 | Feb 3, 2026 | - | - | |
| 4 | Feb 3, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AVIR SEC filings: frequently asked questions
Which institutions hold AVIR stock?
As of June 30, 2026, the largest Atea Pharmaceuticals, Inc. (AVIR) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($55.8 million), BlackRock ($40.5 million), Vanguard Capital Management LLC ($13.8 million), State Street Corp ($7.7 million), Two Sigma Investments ($7.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did AVIR report in its latest 8-K?
Atea Pharmaceuticals, Inc. (AVIR) filed an 8-K on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results announced for the three months ended June 30, 2026.
What are the latest AVIR SEC filings?
Atea Pharmaceuticals, Inc. (AVIR) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and a Form 4 insider filing on June 23, 2026.
What is AVIR's SEC CIK number?
Atea Pharmaceuticals, Inc. (AVIR)'s SEC Central Index Key (CIK) is 1593899. EDGAR lists every AVIR filing under that number.
Ask anything about AVIR
The research agent reads AVIR's filings, financials, insider trades and 13F holders, then answers with sources.